Quantcast
Last updated on April 19, 2014 at 13:20 EDT

Lumenis® Hosts Symposium at the annual COSM in Chicago on April 29th; “˜Controversy in Treatment of Airway Papillomas: Laser or Microdebrider?’

April 26, 2011

Lumenis announced the support of a medical symposium entitled “Controversy in Treatment of Airway Papillomas”, be held on Friday, April 29, 2011, at the annual COSM, in Chicago.

Santa Clara, CA (PRWEB) April 25, 2011

Lumenis Ltd., the world’s largest medical laser company, announced the support of a medical symposium entitled, “Controversy in Treatment of Airway Papillomas,”to be held on Friday, April 29, 2011, at the annual COSM, in Chicago.

Recurrent respiratory papillomatosis (RRP) is the most common non-cancerous tumor of the upper airway in children, caused by HPV; RRP can be carried into adulthood often requiring multiple surgical interventions to maintain a safe airway, till remission or regression occurs. Research and new tools, including the AcuPulse 40WG, are helping to improve patient care, and the two most common tools for surgical removal of tissue are CO2 laser which ablates the tissue and the microdebrider which mechanically shaves off the tissue.

Lumenis will host an expert panel of physicians to discuss treatment preferences using CO2 Laser or the traditional Microdebrider. Dr. Paul Castellanos, Associate Professor of Surgery, Laryngology”“Bronchoesophagology, University of Alabama will moderate the session. Dr. Castellanos whose broad experience using both microdebrider and CO2 laser technologies will aid in the discussion between Dr. Brian Wiatrak, Chief of Pediatric Otolaryngology at Children’s Hospital of Alabama, who uses Microdebrider, and Dr. Mark Courey of the University of California and Director of the Division of Laryngology, who uses CO2 laser.

“The treatment of recurrent respiratory papillomatosis can be a frustrating and difficult process,” commented Dr. Paul Castellanos, the Laryngologist at UAB “trying to control a process that is benign but very damaging to the phonatory mechanism both by itself and from our efforts at surgically trying to bring it under control”. He adds “but recent technology advances have made laser treatment far less damaging. These include advanced scanning CO2 laser delivery systems that allow for greater levels of precision, low thermal damage and speed of the surgery. Microdebrider systems also have a lot to offer with benefits that, in my opinion, complement laser technology. I am looking forward to the discussions around these two competing technology treatment options.”

“Various surgical treatment modes exist for removing papillomas, with the recent launch of the flexible AcuPulse 40 WG FiberLase technology from Lumenis, there is a renewed interest in the use of CO2 lasers, to access the multiple locations where the papilloma tissue can occur. We believe the unprecedented accuracy of the CO2 energy delivery system, coupled with FiberLase flexible technology will, make the CO2 laser system, the platinum standard for safe treatment of (RRP), while maintaining the integrity of the surrounding healthily airways structures”, said Caroline Coyle, Senior Vice President and General Manager of Lumenis’ Surgical Business Unit.

Lumenis encourages physicians to stop by booth #302 after the symposium to receive hands on demos of the AcuPulse 40WG FiberLase and UltraPulse SurgiTouch Freebeam carbon dioxide laser systems. Or visit http://www.surgical.lumenis.com/COSM


About Lumenis

Lumenis, the world’s largest medical laser company, is a global developer, manufacturer and distributor of laser and light-based devices for surgical, ophthalmic and aesthetic applications, with more than 800 employees worldwide. Lumenis has 270 registered patents, over 260 FDA clearances, an installed base of over 30,000 systems and a presence in over 100 countries. Lumenis endeavors to bring the finest state of the art technology products to the market, fulfilling the highest standards of excellence, quality and reliability, delivering premium value and service to its customers. The name Lumenis is derived from the Latin words meaning “Light of Life” highlighting the light, which is the basis of our technologies, used to enhance life. For more information about Lumenis and its products, please visit: http://www.lumenis.com.

For Further Information Contact:

Michelle Maydan

Director of Corporate Communications

1-866-569-0597

+972-4-959-9004

Lumenis® and its logo are trademarks or registered trademarks of the Lumenis Group of Companies.

###

For the original version on PRWeb visit: http://www.prweb.com/releases/prweb2011/4/prweb8342828.htm


Source: prweb